Investigation Launched After Vistagen Stock Plummets 80% Over Drug Candidate Claims

Vistagen Therapeutics Faces Legal Scrutiny as Stock Sinks

On April 28, 2026, Schubert Jonckheer & Kolbe LLP announced that it is investigating Vistagen Therapeutics, Inc. (NASDAQ: VTGN) due to potential legal claims stemming from allegations of misleading statements related to its drug candidate, fasedienol. This scrutiny follows a staggering collapse in the company's stock price, which dropped over 80% in a day, raising serious concerns among investors.

The Stock Drop

The trouble for Vistagen began on December 17, 2025, when the company disclosed that its PALISADE-3 Phase 3 clinical trial did not yield significant results. The study aimed to evaluate fasedienol in treating social anxiety disorder; however, it failed to demonstrate a noteworthy improvement on its primary endpoint, the Subjective Units of Distress Scale. Furthermore, the results did not show any significant difference between the drug and a placebo on secondary metrics.

Following the disappointing trial results, Vistagen’s stock plummeted from $4.36 per share on December 16 to just $0.86 by the close on December 17. This drastic shift raised alarm bells among investors, leading to the submission of a class action lawsuit. The complaint alleges that between April 2024 and December 2025, Vistagen falsely reassured investors regarding the drug's prospects while deliberately concealing negative information about its trial outcomes.

Allegations of Misleading Information

The core of the investigation revolves around claims that Vistagen's leadership provided overly optimistic statements about fasedienol, which misled investors about the drug's potential for success. Investors are encouraged to connect with the investigating law firm to explore their legal options moving forward. The firm is looking into potential misconduct by Vistagen's corporate officers, which could have implications for those invested in the company.

Vistagen Therapeutics, which specializes in developing new treatments for anxiety and depression, has not yet publicly addressed the allegations or the investigation from Schubert Jonckheer. Their lack of transparency could further jeopardize investor trust, especially at a time when they are already reeling from the abrupt stock decline.

What This Means for Investors

For current shareholders of Vistagen, the situation poses several risks. The possibility of legal ramifications could result not only in financial losses but also impact the future viability of the company's operations. Investors are cautioned to assess their positions and consider the uncertainties that lie ahead, particularly as legal inquiries unfold.

This incident serves as a stark reminder of the volatility inherent in biotech investments, where the outcome of clinical trials can drastically sway stock performance. Should the allegations hold merit, there could be significant ramifications for Vistagen's leadership and the future of its drug candidates.

Conclusion

As investigations continue, Vistagen Therapeutics finds itself at a pivotal juncture. With their reputation on the line and investor confidence waning, the coming months could very well determine the fate of this biotech firm. While the dust settles on the implications of the recent trial results, investors must stay informed and vigilant in following this evolving story.